Table 2. Summary of dosing regimens.

Single dosing (and CIV1)
Cohort name	Number of subjects	Dose
C1	8	300 mg oral
C2	8	900 mg oral
C3	8	1200 mg oral
C4	8	1500mg oral
CIV1	8	3 mg/kg intravenous single dose
Multiple dosing (and CIV2)
CM1	8	300–1200 mg oral qds for 2 to 3 days
CM2	8	1500 mg oral (or highest tolerated dose from single dosing) qds for 2 to 3 days
CIV2	8	Depends on emerging data (5–10 mg/kg intravenous) single dose

Additional dosing cohorts may be added depending on emerging safety data. Eight cohorts and the above dose escalations represent the maximum dose increases that would occur assuming reassuring safety data.